Continuing with letrozole offers greater benefits

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Tamoxifen is a standard adjuvant therapy for hormone-responsive early breast cancer in postmenopausal women.
• Limited treatment options exist after 5 years of adjuvant tamoxifen due to lack of further survival benefit.
• Aromatase inhibitors like letrozole are being investigated for extended adjuvant therapy.

Purpose of the Study:

• To review data supporting extended adjuvant letrozole therapy after initial tamoxifen treatment.
• To evaluate the efficacy and safety of extended letrozole in preventing breast cancer recurrence.

Main Methods:

• Review of clinical trial data and cohort analyses on extended adjuvant letrozole therapy.
• Analysis of disease-free survival (DFS) and overall survival (OS) data.
• Assessment of safety profiles, including side effects and quality of life.

Main Results:

• Extended adjuvant letrozole significantly improves DFS over placebo in postmenopausal women completing tamoxifen.
• The therapy is particularly effective in node-positive patients, improving both DFS and OS.
• No significant increase in fractures, endometrial malignancies, hypercholesterolemia, or cardiovascular events was observed.

Conclusions:

• Extended adjuvant letrozole is effective for long-term use in postmenopausal women with early breast cancer.
• It is associated with increased osteoporosis but is otherwise well-tolerated.
• Treatment guidelines recommend at least 2.5 years of extended letrozole, with recent data suggesting longer durations (≥48 months) may offer greater benefit.